Skip to search formSkip to main contentSkip to account menu

RDEA 119

Known as: MEK Inhibitor RDEA119, RDEA-119, RDEA119 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

refametinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Abstract 5253: MEK-ERK pathway inhibition reduces mucin production in a murine xenograft model of pseudomyxoma peritonei
Introduction: Pseudomyxoma peritonei (PMP) is characterized by compressive organ dysfunction from progressive intra-peritoneal… 
2012
2012
Abstract B41: MEK1/2 inhibition with the novel chemotherapeutic agent BAY 86-9766 (RDEA119): A promising treatment strategy for pancreatic cancer.
Introduction: Novel effective agents and improved mouse models for better prediction of clinical efficacy of new therapies for… 
2012
2012
Therapeutic Benefit of Small Molecule Inhibitors of MEK/ERK in Reducing Sickle Red Cell Adhesion and Vaso-Occlusion in Vivo
Abstract 376 In sickle cell disease (SCD), vaso-occlusive crises are caused largely by the sickle erythrocyte (SSRBC), which… 
2011
2011
Abstract 3828: RDEA119 synergy the anti-tumor effect of sorafenib in renal cell carcinoma cells
The MEK signaling pathway is over-expressed in more than 30 percentages of cancers, leading to cell growth and proliferation… 
2011
2011
Cancer Therapy : Preclinical Synergistic Effect between Erlotinib and MEK Inhibitors in KRAS Wild-Type Human Pancreatic Cancer Cells
Purpose: The combination of erlotinib and gemcitabine has shown a small but statistically significant survival advantage when… 
2011
2011
Abstract 5470: Potent MEK inhibitor CIP-137401: Preclinical studies
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL In recent years there is a lot of interest in both pre… 
2011
2011
Abstract A88: Safety, pharmacokinetic, and pharmacodynamic results of BAY 86–9766, an oral MEK inhibitor, in combination with sorafenib, an oral multikinase inhibitor, in advanced cancer patients.
Background: Preclinical data revealed a synergistic interaction between sorafenib (Nexavar®) and BAY 86-9766 (RDEA119). Sorafenib… 
2010
2010
138 Combination of PI3K inhibitor BAY 80-6946 with allosteric MEK inhibitor BAY 86-9766 (RDEA119) and with erlotinib for the treatment of non-small cell lung cancer
2010
2010
140 Combination of PI3K inhibitor BAY 80-6946 and allosteric MEK inhibitor BAY 86-9766 (RDEA119), a promising approach for the treatment of colorectal cancers
2007
2007
RDEA119: A potent and highly selective MEK inhibitor for the treatment of cancer
B120 Introduction: The RAS-RAF-MEK-ERK pathway has emerged as a significant focus for molecular targeted cancer therapy, and MEK… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)